DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twelve patents protecting this drug.
This drug has twenty-seven patent family members in seventeen countries.
The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
A generic version of ADHANSIA XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
Summary for ADHANSIA XR
Recent Clinical Trials for ADHANSIA XR
Identify potential brand extensions & 505(b)(2) entrants
|Purdue Pharma LP||Phase 4|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Purdue Pharma Lp||ADHANSIA XR||methylphenidate hydrochloride||CAPSULE, EXTENDED RELEASE;ORAL||212038-006||Feb 27, 2019||RX||Yes||Yes||Get Started Free||Get Started Free||Y||Get Started Free|
|Purdue Pharma Lp||ADHANSIA XR||methylphenidate hydrochloride||CAPSULE, EXTENDED RELEASE;ORAL||212038-004||Feb 27, 2019||RX||Yes||No||Get Started Free||Get Started Free||Get Started Free|
|Purdue Pharma Lp||ADHANSIA XR||methylphenidate hydrochloride||CAPSULE, EXTENDED RELEASE;ORAL||212038-003||Feb 27, 2019||RX||Yes||No||Get Started Free||Get Started Free||Y||Get Started Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|